Allergan Highlights Botox, Retina Programs; Overactive Bladder Next Botox Claim?
This article was originally published in Pharmaceutical Approvals Monthly
Allergan and partner Sirna hope to advance novel RNAi-based retinal disease agent Sirna-027 into Phase II trials for macular degeneration this year, according to Allergan
You may also be interested in...
Allergan plans to submit a macular edema NDA for Posurdex (dexamethasone) in late 2006 or early 2007, the company says May 3. The firm is highlighting less frequent dosing it says is possible with the extended-release drug delivery technology used in the proprietary dexamethasone formulation (1Pharmaceutical Approvals Monthly February 2006, p. 16). Allergan notes it also has completed preclinical studies of Posurdex in combination with anti-VEGF agents for treatment of macular degeneration. Genentech's VEGF agent Lucentis (ranibizumab) has a June 29 priority review user fee date for macular degeneration (2Pharmaceutical Approvals Monthly March 2006, In Brief)...
The slow-down in year-end FDA submissions in recent years appears to have stabilized in 2005, with 16 filings in December – up slightly from 13 in December 2004.
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011